FDA Oncology Announcements

VEGFR inhibitor × Endocrine × Clear all

2 Announcements

FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinal

FDA approves cabozantinib for differentiated thyroid cancer

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Condition: Endocrine